title: Isolated esophageal ulcerations in immunocompromised patients:  mycophenolate mofetil or foscarnet, who is guilty?
authors.forename: Stephanie
authors.initials: S
authors.lastname: Haouy
authors.forename: Fanny
authors.initials: F
authors.lastname: Rocher
authors.forename: Marilyne
authors.initials: M
authors.lastname: Poirée
authors.forename: Marie-Christine
authors.initials: MC
authors.lastname: Saint-Paul
authors.forename: Stephanie
authors.initials: S
authors.lastname: De Smet
authors.forename: Anne
authors.initials: A
authors.lastname: Sirvent
authors.forename: Nicolas
authors.initials: N
authors.lastname: Sirvent
mesh_terms: D000293:Adolescent; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D000998:Antiviral Agents / Q000009:adverse effects; D003586:Cytomegalovirus Infections / Q000188:drug therapy*; D004935:Esophageal Diseases / Q000139:chemically induced*; D005260:Female; D017245:Foscarnet / Q000009:adverse effects*; D006801:Humans; D016867:Immunocompromised Host; D009173:Mycophenolic Acid / Q000009:adverse effects / Q000031:analogs & derivatives*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D014456:Ulcer / Q000139:chemically induced
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000998:Antiviral Agents; D017245:Foscarnet; D009173:Mycophenolic Acid